pharma · Plaque Psoriasis · Diabetic Macular Edema
Bausch + Lomb
Bausch & Lomb Incorporated
Bausch & Lomb is a pharma organization headquartered in Rochester, US. Primary therapeutic focus areas include Plaque Psoriasis, Diabetic Macular Edema. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and
Rochester, IN HQ
1853 Founded
38 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Rochester, IN
- Founded
- 1853
- Employees
- 38
- Programs
- 3
- Drugs
- 5
- Patents
- 25
0.59 mg fluocinolone acetonide intravitreal implant
Phase 2 · small molecule · Diabetic Macular Edema
0.59 mg fluocinolone acetonide intravitreal implant for Diabetic Macular Edema is a Phase 2 program (small_molecule) at Bausch & Lomb Incorporated with 1 ClinicalTrials.gov record(s).
Internal code 420-003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bausch & Lomb Incorporated
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Diabetic Macular Edema
- Status
- completed
- Trials
- 1